In this report, the Cancer Drugs market is expected to be valued at USD xxx billion by 2026, growing at a CAGR of xx% between 2020 and 2026. In this study, sales and sales value (million USD) of major players in Europe market will be included.
Sales and revenue by type/application from 2014-2026.
Industry chain, market trend, downstream and upstream information is also included.
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cancer Drugs for these regions, from 2014 to 2026 (forecast), including
Germany
UK
France
Russia
Benelux
Italy
Spain
Europe Cancer Drugs market competition by top manufacturers/players, with Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co.
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Merck KGaA
Ipsen
AbbVie
Gilead Sciences
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cancer Drugs for each application, including
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Cancer Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.1.1 Chemotherapy Market Performance (Volume)
2.1.2 Targeted Therapy Market Performance (Volume)
2.1.3 Immunotherapy Market Performance (Volume)
2.1.4 Hormonal Therapy (Biologic Therapy) Market Performance (Volume)
2.1.5 Others Market Performance (Volume)
2.2 Overall Market Performance(Value)
2.2.1 Chemotherapy Market Performance (Value)
2.2.2 Targeted Therapy Market Performance (Value)
2.2.3 Immunotherapy Market Performance (Value)
2.2.4 Hormonal Therapy (Biologic Therapy) Market Performance (Value)
2.2.5 Others Market Performance (Value)
3 Product Application Market
3.1 Overall Market Performance (Volume)
3.1.1 Blood Cancer Market Performance (Volume)
3.1.2 Breast Cancer Market Performance (Volume)
3.1.3 Gastrointestinal Cancer Market Performance (Volume)
3.1.4 Prostate Cancer Market Performance (Volume)
3.1.5 Respiratory/Lung Cancer Market Performance (Volume)
3.1.6 Other Cancers Market Performance (Volume)
4 Manufacturers Profiles/Analysis
4.1 Roche
4.1.1 Roche Profiles
4.1.2 Roche Product Information
4.1.3 Roche Cancer Drugs Business Performance
4.1.4 Roche Cancer Drugs Business Development and Market Status
4.2 Novartis
4.2.1 Novartis Profiles
4.2.2 Novartis Product Information
4.2.3 Novartis Cancer Drugs Business Performance
4.2.4 Novartis Cancer Drugs Business Development and Market Status
4.3 Celgene
4.3.1 Celgene Profiles
4.3.2 Celgene Product Information
4.3.3 Celgene Cancer Drugs Business Performance
4.3.4 Celgene Cancer Drugs Business Development and Market Status
4.4 Bristol-Myers Squibb
4.4.1 Bristol-Myers Squibb Profiles
4.4.2 Bristol-Myers Squibb Product Information
4.4.3 Bristol-Myers Squibb Cancer Drugs Business Performance
4.4.4 Bristol-Myers Squibb Cancer Drugs Business Development and Market Status
4.5 Amgen
4.5.1 Amgen Profiles
4.5.2 Amgen Product Information
4.5.3 Amgen Cancer Drugs Business Performance
4.5.4 Amgen Cancer Drugs Business Development and Market Status
4.6 Johnson & Johnson
4.6.1 Johnson & Johnson Profiles
4.6.2 Johnson & Johnson Product Information
4.6.3 Johnson & Johnson Cancer Drugs Business Performance
4.6.4 Johnson & Johnson Cancer Drugs Business Development and Market Status
4.7 Pfizer
4.7.1 Pfizer Profiles
4.7.2 Pfizer Product Information
4.7.3 Pfizer Cancer Drugs Business Performance
4.7.4 Pfizer Cancer Drugs Business Development and Market Status
4.8 Takeda
4.8.1 Takeda Profiles
4.8.2 Takeda Product Information
4.8.3 Takeda Cancer Drugs Business Performance
4.8.4 Takeda Cancer Drugs Business Development and Market Status
4.9 Eli Lilly
4.9.1 Eli Lilly Profiles
4.9.2 Eli Lilly Product Information
4.9.3 Eli Lilly Cancer Drugs Business Performance
4.9.4 Eli Lilly Cancer Drugs Business Development and Market Status
4.10 AstraZeneca
4.10.1 AstraZeneca Profiles
4.10.2 AstraZeneca Product Information
4.10.3 AstraZeneca Cancer Drugs Business Performance
4.10.4 AstraZeneca Cancer Drugs Business Development and Market Status
4.11 Astellas
4.12 Merck & Co.
4.13 Sanofi
4.14 Bayer
4.15 Biogen Idec
4.16 Eisai
4.17 Teva
4.18 Otsuka
4.19 Merck KGaA
4.20 Ipsen
4.21 AbbVie
4.22 Gilead Sciences
5 Market Performance for Manufacturers
5.1 Europe Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
5.2 Europe Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
5.3 Europe Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
5.4 Europe Cancer Drugs Gross Margin of Manufacturers 2014-2020
5.5 Market Concentration
6 Regions Market Performance for Manufacturers
6.1 Germany Market Performance for Manufacturers
6.1.1 Germany Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.1.2 Germany Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.1.3 Germany Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.1.4 Germany Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.1.5 Market Concentration
6.2 UK Market Performance for Manufacturers
6.2.1 UK Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.2.2 UK Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.2.3 UK Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.2.4 UK Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.2.5 Market Concentration
6.3 France Market Performance for Manufacturers
6.3.1 France Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.3.2 France Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.3.3 France Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.3.4 France Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.3.5 Market Concentration
6.4 Russia Market Performance for Manufacturers
6.4.1 Russia Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.4.2 Russia Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.4.3 Russia Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.4.4 Russia Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.4.5 Market Concentration
6.5 Benelux Market Performance for Manufacturers
6.5.1 Benelux Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.5.2 Benelux Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.5.3 Benelux Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.5.4 Benelux Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.5.5 Market Concentration
6.6 Italy Market Performance for Manufacturers
6.6.1 Italy Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.6.2 Italy Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.6.3 Italy Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.6.4 Italy Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.6.5 Market Concentration
6.7 Spain Market Performance for Manufacturers
6.7.1 Spain Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.7.2 Spain Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.7.3 Spain Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.7.4 Spain Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.7.5 Market Concentration
6.8 Market Performance for Manufacturers
6.8.1 Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.8.2 Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.8.3 Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.8.4 Cancer Drugs Gross Margin of Manufacturers 2014-2020
6.8.5 Market Concentration
7 Europe Cancer Drugs Market Performance (Sales Point)
7.1 Europe Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
7.2 Europe Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
7.3 Europe Cancer Drugs Price (USD/Unit) by Regions 2014-2020
7.4 Europe Cancer Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions (Sales Point)
8.1 Europe Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.2 Germany Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.3 UK Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.4 France Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.5 Russia Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.6 Benelux Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.7 Italy Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.8 Spain Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
9 Upstream Source, Technology and Cost
9.1 Upstream Source
9.2 Technology
9.3 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Distributors
11 Consumer Analysis
11.1 Blood Cancer Industry
11.2 Breast Cancer Industry
11.3 Gastrointestinal Cancer Industry
11.4 Prostate Cancer Industry
11.5 Respiratory/Lung Cancer Industry
11.6 Other Cancers Industry
12 Market Forecast 2021-2026
12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
12.1.1 Europe Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
12.1.2 Europe Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
12.1.3 Germany Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.4 UK Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.5 France Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.6 Russia Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.7 Benelux Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.8 Italy Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.9 Spain Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
12.2.1 Overall Market Performance
12.2.2 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2.3 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2.4 Immunotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2.5 Hormonal Therapy (Biologic Therapy) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2.6 Others Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.3 Sales Forecast by Application 2021-2026
12.3.1 Overall Market Performance
12.3.2 Blood Cancer Sales and and Growth Rate 2021-2026
12.3.3 Breast Cancer Sales and and Growth Rate 2021-2026
12.3.4 Gastrointestinal Cancer Sales and and Growth Rate 2021-2026
12.3.5 Prostate Cancer Sales and and Growth Rate 2021-2026
12.3.6 Respiratory/Lung Cancer Sales and and Growth Rate 2021-2026
12.3.7 Other Cancers Sales and and Growth Rate 2021-2026
12.4 Price (USD/Unit) and Gross Profit Forecast
12.4.1 Europe Cancer Drugs Price (USD/Unit) Trend 2021-2026
12.4.2 Europe Cancer Drugs Gross Profit Trend 2021-2026
13 Conclusion
Executive Summary
Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentatio...
Industrial protective clothing constitutes specialized attire fabricated from engineered textiles intended to safeguard personnel operating amid potentially perilous occupational environments from exposure to myriad hazards inherent to industrial settings such as manufacturing plants, construction s...
Executive Summary
Azoth Analytics has released a research report titled "Global Antibiotic Drugs Market (2024 Edition)" which provides a complete analysis of the global Antibiotic Drugs industry in terms of market segmentation By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoro...
Europe cutting tools market was valued at $6.85 billion in 2023 and will grow by 4.6% annually over 2023-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for power tools for DIY activ...
Europe paper machine clothing (PMC) market was valued at $ 631.1 million in 2023 and will grow by 3.6% annually over 2023-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking process, the intro...
Europe endoscopy devices market was valued at $10.1 billion in 2023 and will grow by 5.9% annually over 2023-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic components, growing ge...
Europe digital health and wellness market was valued at $100.9 billion in 2023 and will grow by 18.9% annually over 2023-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphones and wearable devic...
Europe connected healthcare device market was valued at $16 billion in 2023 and will grow by 19.2% annually over 2023-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetration of mobile and inte...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...